How could Myfortic® make the difference for your transplant care?
Myfortic® remains intact in the acid environment of the stomach with a pH <5 1
Myfortic® only allows MPA release until it reaches the small intestine with an environment pH >5 1
MPA release over time for Myfortic® 360 mg tablets at pH 5.0-6.8 1
Myfortic ® and MMF provide similar MPA exposure (AUC) in renal transplant patients1
Myfortic ® sustains MPA exposure even when co-administered with PPI2
Abbreviations:
MMF: mycophenolate mofetil; GI: gastrointestinal; MPA: mycophenolic acid; AUC: area under the curve; NS: non-significant
References:
1. Arns W, et al. Clin Transplant. 2005;19(2):199-206 2. Rupprecht K, et al. J Clin Pharmacol. 2009;49(10):1196-1201.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
Please visit https://www.novartis.com/sg-en/product-list/myfortic to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.
FA-11484251_2027Aug05